Literature DB >> 3190993

Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol.

R O Day1, J Miners, D J Birkett, G G Graham, A Whitehead.   

Abstract

1. 1-methyl xanthine (1-MX) is metabolized exclusively to 1-methyl uric acid (1-MU) by the enzyme xanthine oxidase. 2. The ratio of 1-MU to 1-MX in the urine, following a dose of 50 mg of 1-MX infused intravenously over 20 min, was used to measure the inhibition of xanthine oxidase induced by different doses of allopurinol. 3. Normal volunteers (n = 8) were given allopurinol 50, 100, 300 and 600 mg daily for 1 week each, in random order and 1 week separated each treatment. Inhibition of xanthine oxidase was assessed twice, on the last 2 days of each treatment week. 4. Steady-state oxipurinol concentrations increased linearly with increasing dose of allopurinol. 5. There was a hyperbolic relationship between the 1-MU/1-MX ratio and plasma oxipurinol concentrations, with an initial steep decline in the ratio which plateaued when plasma oxipurinol was around 4-6 mg l-1. This reduction in the ratio was quickly reversible upon cessation of allopurinol. 6. The 50% and 90% effective inhibitory oxipurinol concentrations, in relation to the 1-MU-/1-MX ratio were 1.4 +/- 0.46 and 4.08 +/- 2.03 mg l-1 respectively. 7. The concentration of oxipurinol required for almost complete inhibition of the enzyme was substantially less than those often observed in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3190993      PMCID: PMC1386565          DOI: 10.1111/j.1365-2125.1988.tb03402.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  CLINICAL, PHYSIOLOGICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH XANTHINURIA AND PHEOCHROMOCYTOMA.

Authors:  K ENGELMAN; R W WATTS; J R KLINENBERG; A SJOERDSMA; J E SEEGMILLER
Journal:  Am J Med       Date:  1964-12       Impact factor: 4.965

2.  Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT.

Authors:  P V Pedersen
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Variations in allopurinol metabolism by xanthinuric subjects.

Authors:  H A Simmonds; B Levin; J S Cameron
Journal:  Clin Sci Mol Med       Date:  1974-08

4.  Urinary excretion of 6 hydroxylated metabolite and oxypurines in a xanthinuric man given allopurinol or thiopurinol.

Authors:  C Auscher; C Pasquier; N Mercier; F Delbarre
Journal:  Adv Exp Med Biol       Date:  1974       Impact factor: 2.622

5.  A comparison of the specificities of xanthine oxidase and aldehyde oxidase.

Authors:  T A Krenitsky; S M Neil; G B Elion; G H Hitchings
Journal:  Arch Biochem Biophys       Date:  1972-06       Impact factor: 4.013

6.  Inhibition of urate production by allopurinol.

Authors:  T Spector
Journal:  Biochem Pharmacol       Date:  1977-03-01       Impact factor: 5.858

7.  High-performance liquid chromatographic assay for allopurinol and oxipurinol in human plasma.

Authors:  W G Kramer; S Feldman
Journal:  J Chromatogr       Date:  1979-01-01

8.  Metabolic studies of allopurinol, an inhibitor of xanthine oxidase.

Authors:  G B Elion; A Kovensky; G H Hitchings
Journal:  Biochem Pharmacol       Date:  1966-07       Impact factor: 5.858

9.  Theophylline metabolism by the rat liver microsomal system.

Authors:  S M Lohmann; R P Miech
Journal:  J Pharmacol Exp Ther       Date:  1976-01       Impact factor: 4.030

10.  The conversion of 4-hydroxypyrazolo[3,4-d]pyrimidine (allopurinol) into 4,6-dihroxypyrazolo[3,4-d]pyrimidine (Oxipurinol) in vivo in the absence of xanthine-oxen oxidoreductase.

Authors:  R A Chalmers; R Parker; H A Simmonds; W Snedden; R W Watts
Journal:  Biochem J       Date:  1969-05       Impact factor: 3.857

View more
  13 in total

1.  Xanthine oxidase does not contribute to impaired peripheral conduit artery endothelium-dependent dilatation with ageing.

Authors:  Iratxe Eskurza; Zachary D Kahn; Douglas R Seals
Journal:  J Physiol       Date:  2006-01-26       Impact factor: 5.182

Review 2.  New uses for allopurinol.

Authors:  R O Day; D J Birkett; M Hicks; J O Miners; G G Graham; P M Brooks
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

Review 3.  Allopurinol, uric acid, and oxidative stress in cardiorenal disease.

Authors:  Markus Riegersperger; Adrian Covic; David Goldsmith
Journal:  Int Urol Nephrol       Date:  2011-03-10       Impact factor: 2.370

4.  Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.

Authors:  I Walter-Sack; J X de Vries; C Kutschker; A Ittensohn; A Voss
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

5.  Honorary Professor Garry Graham.

Authors:  Richard O Day; Kenneth M Williams; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2021-09-17       Impact factor: 4.473

6.  1-Methylxanthine derived from theophylline as an in vivo biochemical probe of allopurinol effect.

Authors:  D J Birkett; J O Miners; R O Day
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

7.  Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. I. Uric acid kinetics.

Authors:  W Löffler; R Landthaler; J X de Vries; I Walter-Sack; A Ittensohn; A Voss; N Zöllner
Journal:  Clin Investig       Date:  1994-12

Review 8.  Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.

Authors:  Richard O Day; Garry G Graham; Mark Hicks; Andrew J McLachlan; Sophie L Stocker; Kenneth M Williams
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

9.  Lack of a pharmacokinetic interaction between oral famciclovir and allopurinol in healthy volunteers.

Authors:  S E Fowles; S K Pratt; J Laroche; W T Prince
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques.

Authors:  A J McLachlan; S E Tett; D J Cutler; R O Day
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.